QazCoVac-P -COVID-19 Subunit Vaccine
Randomized, Blind, Placebo-controlled Phase- I Study and Randomized, Open Phase Phase-II Study of QazCoVac-P - COVID-19 Subunit Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Совмещённое исследование фаз Фаза I–II: Фаза I — первое применение у людей. Проверяют безопасность и подбирают дозу, участников немного. Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- В исследовании участвуют здоровые добровольцы.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–100 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 244 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (12.2021) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 11 · невключение: 19
Критерии включения
- Availability of signed and dated informed consent of the volunteer to
- participate in the study
- Healthy male and female volunteers aged 18-50 and 50 and above.
- Ability and voluntary desire to independently keep records in the SelfObservation Diary, as well as to carry out all the repeated visits provided for in the study for control medical observation.
- The voluntary desire of females to use methods of reliable contraception throughout the entire period of their participation in the study.
- Negative results for IgM and IgG antibodies to SARS-CoV-2.
- Absence of COVID-19 diagnosis in history.
- Absence in the last 14 days of close contact with persons suspected of being infected with SARS-CoV-2, or persons whose diagnosis of COVID-19 has been confirmed with laboratory.
- Negative test results for human immunodeficiency virus (HIV), hepatitis B and hepatitis C.
- Negative PCR results for coronavirus SARS-CoV-2
- According to the results of a chest x-ray, there is no pathological process in the lungs.
Критерии невключения
- Aggravated allergic history, drug intolerance, including hypersensitivity to any of the components of the study drug, as well as a history of serious adverse events during vaccine administration (such as allergic reactions, respiratory failure, angioedema, abdominal pain).
- Acute illness with a fever (body temperature ≥37.1°C) at the time of screening/randomization.
- Chronic alcohol and/or drug use in history.
- Clinically significant deviations from normal values during laboratory and/or imaging at screening.
- Women with a positive urine pregnancy test.
- Simultaneous treatment with immunosuppressive drugs, including corticosteroids (2 weeks) 4 weeks prior to study drug administration.
- Acute or chronic clinically significant lesions of the lungs, cardiovascular system, gastrointestinal tract, liver, blood system, skin, endocrine, neurological and psychiatric diseases or impaired renal function (asthma, diabetes, thyroid disease, arrhythmia, myocardial infarction, severe hypertension not controlled by drugs, etc.), identified based on medical history, physical examination or clinical laboratory tests that, according to the researcher, may affect the study result.
- Disruption of platelets or other blood clotting disorders, which may cause contraindications to intramuscular administration.
- Leukemia or neoplasm in history.
- Persons with autoimmune diseases.
- Volunteers who received antiviral drugs, immunoglobulin's or blood transfusions or any other investigational drug within 4 weeks prior to study drug administration;
- Volunteers who received anti-inflammatory drugs 2 days before study drug
- administration;
- Participation in any other clinical research within the last 3 months;
- Volunteers with a concern that they will not comply with the study requirements, or persons with severe physical or mental disabilities that may affect the completion of the study;
- Negative PCR results for coronavirus SARS-CoV-2;
- According to the results of a chest x-ray, there is no pathological process in the lungs;
- Voluntary refusal to study;
- Vulnerable Volunteers of research.
Источник: ClinicalTrials.gov, NCT04930003 · запись обновлена в реестре 7 декабря 2023.
Дизайн и результаты
Что измеряют — первичные конечные точки (3), вторичных — 1
- Frequency of adverse events up to seven days after immunization — Seven days after each immunization
- Frequency of adverse events up to 21 days after immunization — 21 days after each immunization
- The proportion of volunteers with increased levels of the immune response of specific neutralizing antibody titers in ELISA following the vaccination, compared with a placebo — at days 0, 21, 27, 42, 90, 180
Цель исследования
Randomized, Blind, Placebo-controlled Phase- I Study and Randomized, Open Phase Phase-II Study of QazCoVac-P - COVID-19 Subunit Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT04930003 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.